Interim data on Alnylam's drug shows efficacy in late-stage trial

Alnylam Pharmaceuticals Inc said on Thursday early data from a late-stage trial testing of its gene-silencing drug for a rare, painful genetic disease showed effectiveness, putting the firm on track for a faster approval from U.S. regulators.